Targeted plasma proteomics reveals signatures discriminating COVID-19 from sepsis with pneumonia

Laura M Palma Medina,Haris Babačić,Majda Dzidic,Åsa Parke,Marina Garcia,Kimia T Maleki,Christian Unge,Magda Lourda,Egle Kvedaraite,Puran Chen,Jagadeeswara Rao Muvva,Martin Cornillet,Johanna Emgård,Kirsten Moll,Karolinska K. I./K. COVID-19 Study Group,Jakob Michaëlsson,Malin Flodström-Tullberg,Susanna Brighenti,Marcus Buggert,Jenny Mjösberg,Karl-Johan Malmberg,Johan K Sandberg,Sara Gredmark-Russ,Olav Rooyackers,Mattias Svensson,Benedict J Chambers,Lars I Eriksson,Maria Pernemalm,Niklas K Björkström,Soo Aleman,Hans-Gustaf Ljunggren,Jonas Klingström,Kristoffer Strålin,Anna Norrby-Teglund

DOI: https://doi.org/10.1186/s12931-023-02364-y

2023-02-24

Abstract:Background: COVID-19 remains a major public health challenge, requiring the development of tools to improve diagnosis and inform therapeutic decisions. As dysregulated inflammation and coagulation responses have been implicated in the pathophysiology of COVID-19 and sepsis, we studied their plasma proteome profiles to delineate similarities from specific features. Methods: We measured 276 plasma proteins involved in Inflammation, organ damage, immune response and coagulation in healthy controls, COVID-19 patients during acute and convalescence phase, and sepsis patients; the latter included (i) community-acquired pneumonia (CAP) caused by Influenza, (ii) bacterial CAP, (iii) non-pneumonia sepsis, and (iv) septic shock patients. Results: We identified a core response to infection consisting of 42 proteins altered in both COVID-19 and sepsis, although higher levels of cytokine storm-associated proteins were evident in sepsis. Furthermore, microbiologic etiology and clinical endotypes were linked to unique signatures. Finally, through machine learning, we identified biomarkers, such as TRIM21, PTN and CASP8, that accurately differentiated COVID-19 from CAP-sepsis with higher accuracy than standard clinical markers. Conclusions: This study extends the understanding of host responses underlying sepsis and COVID-19, indicating varying disease mechanisms with unique signatures. These diagnostic and severity signatures are candidates for the development of personalized management of COVID-19 and sepsis.